Core Viewpoint - The company expects significant revenue growth and a reduction in net loss for the fiscal year 2025 compared to the fiscal year ending December 31, 2024, driven by improvements in management, marketing strategies, and product distribution channels [1][2]. Group 1: Revenue and Loss Projections - The company anticipates revenue of approximately RMB 4.46 billion to RMB 4.93 billion for the fiscal year 2025, representing an increase of about 71.8% to 89.9% compared to the RMB 2.6 billion revenue for the fiscal year ending December 31, 2024 [1]. - The expected net loss for fiscal year 2025 is projected to be around RMB 1.57 billion to RMB 1.97 billion, which is a decrease of approximately 23.9% to 39.3% from the net loss of RMB 2.59 billion for the fiscal year ending December 31, 2024 [1]. Group 2: Factors Contributing to Growth - The increase in revenue and reduction in net loss are primarily attributed to the enhancement of the company's quality management system, which has improved product quality and reduced sales costs [2]. - The implementation of digital marketing strategies has led to more efficient use of marketing expenses, supporting revenue growth while lowering sales costs [2]. - The company has expanded its product delivery to cover 232 disease control centers and 2,563 vaccination clinics, providing more options for consumers and directly contributing to revenue growth [2]. - Despite a significant increase in listing expenses for 2025, the combination of revenue growth and tightened cost control has resulted in a further narrowing of net loss [2].
中慧生物-B预计年度营业收入约4.46亿元至4.93亿元 同比增加约71.8%至89.9%